Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis | eLife
High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer | Experimental & Molecular Medicine
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Disarming mutant p53 oncogenic function - ScienceDirect
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells | Breast Cancer Research | Full Text
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma | NEJM
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology
TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database | bioRxiv
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer | Accounts of Chemical Research
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - ScienceDirect
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma - eBioMedicine
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm | ACS Chemical Biology
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
